Drug repurposing for COVID-19: current evidence from randomized controlled adaptive platform trials and living systematic reviews.
COVID-19 的藥物再利用:來自隨機對照適應性平台試驗和活性系統性評論的最新證據。
Br Med Bull 2023-09-27
Pioglitazone, a PPAR-y agonist, as one of the new therapeutic candidates for C3 glomerulopathy.
Pioglitazone,一種PPAR-γ激動劑,作為C3腎球病的新治療候選藥物之一。
Pediatr Nephrol 2023-11-30
[State-of-the-art trends in the treatment of immune-mediated inflammatory kidney diseases: Translation of the fundamental science into clinical practice. A review].
免疫介導性炎症性腎疾病治療的最新趨勢:將基礎科學轉化為臨床實踐。一項綜述。
Ter Arkh 2024-01-06
Potential Role of Mineralocorticoid Receptor Antagonists in Nondiabetic Chronic Kidney Disease and Glomerular Disease.
非糖尿病慢性腎病及腎小球疾病中礦物皮質激素受體拮抗劑的潛在角色。
Clin J Am Soc Nephrol 2024-07-22